Under the Paperwork Reduction Act of 199	S. до ратвоп	s are required to respond to	U.S. Patent s 18.collection	Appr Approduced Approduced in the Approximation of	oved for nark Offic fon unles	PTO/\$8/21 (09-0) use through 07/31/2005. OMB 0651-003 SE; U.S. DEPARTMENT OF COMMERC SE it disables a valid OMP content.	
		Application Number		64,855		A TO SHOULD BE S	
TRANSMITTAL		Filing Date	Sep	tember 2	22. 200	3	
FORM		First Named Inventor	<del></del>	hard JAE		<u>*</u>	
		Art Unit	162				
(to be used for all correspondence after Initia	l filha)	Examiner Name	NW.	A O NUCL	A Ch.		
Total Number of Pages in This Submission 13 pgs.		Attorney Docket Numb			IICHA, Chukwuma Q.		
Total Number of Pages in This Submission 13 pgs.   Michies Docket Number   DEAV2001/0045 US NP 2							
ENCLOSURES (Check all that apply)							
Fee Transmittal Form Fee Attached	Drawing(s) Licensing-related Papers				I App	r Allowance Communication to TC est Communication to Board posts and Interferences	
Amendment/Repty After Final Aftidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement  Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	P. P	atilion edition to Convert to a rovisional Application ower of Attorney, Revoce thange of Correspondence arminal Disclaimer equest for Refund D, Number of CD(s) Landscape Table on amental Amendment and	ce Address	-	App (App Prop State	eal Communication to TC real Notice, Brief, Reply Brief) prietary Information us Letter er Enclosure(s) (please Identify	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm Name AVENTIS PHARMACEUTICALS INC.							
Signature Balanam Guage							
Balaram Gupta	Balaram Gupta						
Date August 23, 2005	August 23, 2005 Reg. No. 40,009						
		TE OF TRANSMIS					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. (USPTO EAX NO. 571-272 8700)							
the date shown below: (USPTO FAX NO. 57 Signature	1-273-830	Tleads	ages Trans	smitted: _	13 pgs	<u>)</u>	
Typed or printed name Maribel Mendez					Date	August 23, 2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form analyst suggestions for reducing this burden, should be sant to the Chief Information Officer, U.S. Patent and ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## **PATENT**

Docket No.: DEAV2001/0045-US-NP2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Gerhard Jaehne, et al.

Serial No.: 10/664,855

Filed:

September 22, 2003

Title:

C2-Substituted Indan-1-ols and Their

Derivatives, Processes for Their Preparation and Their Use as

**Pharmaceuticals** 

Examiner:

Nwaonicha, Chukwuma O.

Art Unit:

1621

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile in the Commissioner for Patents, Alexandria, VA 22313, at (571) 273-8300 on

Date of Transmission Mendez
Signature

Date of Transmission

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Arlington, VA 22313-1450

## SUPPLEMENTAL AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 AND REPLY PURSUANT TO 37 C.F.R. § 1.111

Sir:

This is a supplemental response and Rule 111 Amendment in the above-identified patent application in response to telephone call initiated by the Examiner on August 22, 2005. It is respectfully requested that the following remarks be entered in this case.

Amendments to claims start on page 2.

Remarks to amendments and the outstanding office action begin on page 11.

DEAV2001/0045-US-NP2

-1 of 12-